Varenicline and Accelerated Transcranial Magnetic Stimulation (TMS) for Quitting Nicotine Use (Pilot Study)
Launched by MASSACHUSETTS GENERAL HOSPITAL ยท
Trial Information
Current as of September 12, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying whether combining a medication called varenicline with a treatment called accelerated Transcranial Magnetic Stimulation (TMS) can help adults stop using nicotine products like cigarettes or vapes. Varenicline is a pill that helps reduce cravings and withdrawal symptoms, while TMS is a non-invasive procedure that uses magnetic pulses to stimulate parts of the brain involved in addiction. The study will compare people who get varenicline plus real TMS to those who get varenicline plus a fake (inactive) TMS, to see if the real TMS helps more people quit and feel less craving.
Adults who use nicotine and want to quit may be eligible to join. Participants will take varenicline daily for 12 weeks, try to stop using nicotine by the end of the second week, and receive five days of TMS treatments in a row during the study. They will also have two brain scans and complete short weekly check-ins and daily surveys during the treatment period. This study is not yet recruiting, and people of all genders within the age range of about 18 to 74 years may be able to participate. The goal is to find better ways to support people in quitting nicotine for good.
Gender
ALL
Eligibility criteria
About Massachusetts General Hospital
Massachusetts General Hospital (MGH) is a leading academic medical center located in Boston, Massachusetts, renowned for its commitment to advancing medical research and patient care. As a prominent teaching hospital affiliated with Harvard Medical School, MGH plays a pivotal role in clinical trials across a wide range of disciplines, including cardiology, oncology, neurology, and more. The institution is dedicated to fostering innovative research that translates into effective therapies and improved health outcomes. MGH's Clinical Trials Office provides comprehensive support to facilitate the design, implementation, and management of clinical studies, ensuring adherence to the highest ethical standards and regulatory compliance. With a focus on collaboration and patient-centered care, MGH strives to enhance medical knowledge and contribute to the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Jodi M Gilman, PhD
Principal Investigator
Massachusetts General Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported